Biomedicines · 2020 · 17 citations · 25 references
MedicineOncologyPharmacologyApoptosisCancer PharmacologyMolecular OncologyApoptosis In CancerCell DeathIntrinsic Apoptotic PathwayKidney CancerReactive Oxygen SpeciesRenal Cell CarcinomaAnticancer ActivityApoptosis In Renal CellsHyperthermiaMitochondrial Apoptosis SignalingMitochondrial Pathway Of ApoptosisReactive Oxygen Species GenerationReactive Oxygen Species-induced ApoptosisReactive Oxygen Species-mediated Cell Death
Renal cell carcinoma (RCC) represents the most common form of kidney cancer, which accounts for 3-5% newly diagnosed cancer cases. Since limited therapies are available for RCC, a search for new options is required. Therefore, in this study, we evaluated the combination effect of cinnamaldehyde (CNM) and hyperthermia treatment. CNM treatment combined with 43 °C hyperthermia synergistically increased cytotoxicity in RCC cell line ACHN cells. Through Western blot assays, we observed increased apoptosis signaling and decreased proliferation/metastasis signaling, along with a repressed heat shock protein 70 level. In flow cytometry analyses, CNM and hyperthermia combination clearly induced apoptosis and mitochondrial potential of ACHN cells, while arresting the cell cycle. Investigation of reactive oxygen species (ROS) suggested a significant increase of ROS generation by CNM and 43 °C hyperthermia co-treatment. We could verify that ROS is crucial in the apoptotic action of combination treatment with CNM and hyperthermia through further experiments regarding an ROS scavenger. Overall, we suggest CNM and hyperthermia combination treatment as an alternative option of anticancer strategies for RCC.
25
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2018 · 17K citations · Full text
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Bernard Escudier, Camillo Porta, Manuela Schmidinger et al. · Annals of Oncology · 2014 · 2.3K citations · Full text
Medicine, Nephrology, Oncology +14